Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

Hassan, Raffit; Thomas, Anish; Nemunaitis, John; R. Patel, Manish; Bennouna, Jaafar; L. Chen, Franklin; Delord, Jean‐Pierre; Dowlati, Afshin; T. Kochuparambil, Samith; H. Taylor, Matthew; D. Powderly, John; N. Vaishampayan, Ulka; F. Verschraegen, Claire; Grote, H.; von Heydebreck, Anja; M. Chin, Kevin; L. Gulley, James

doi:10.1001/jamaoncol.2018.5428

Public

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

Published in JAMA Oncology • Jan 3, 2019

Authors:

Raffit Hassan

Anish Thomas

John Nemunaitis

Abstract

Importance: Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti-programmed cell death 1 (PD-1) antibodies have antitumor activity in this disease, but little is known about the activity of anti-programmed cell death lig...

Subject

Medicine

Avelumab

Mesothelioma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!